sphingotec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. Read More...
COMBINING INNOVATIVE BIOMARKER WITH OUTSTANDING TECHNOLOGY
sphingotec raises €20 million from HBM and Wellington Partners
sphingotec is adding an advanced POC testing platform to portfolio
Medical leaders support novel theranostic approach to help patients with leaky blood vessels
Ortho Clinical Diagnostics and sphingotec Announce Strategic Agreement Regarding Novel Biomarker for Decreasing Re-hospitalizations in Heart Failure